Idiopathic Pulmonary Fibrosis (IPF) | Norton Healthcare

Indication: Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 In Subjects With Idiopathic Pulmonary Fibrosis (IPF)

With forced vital capacity(FVC) = 45% of predicted

Drug Study

Principal Investigator: David Winslow, M.D.
Norton Pulmonary Specialists, Norton Sleep Center

Sponsor: Nitto Denko Corporation

Email for more information: NCRG@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.